Compare Becton Dickinson and Co (BDX) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Royal Bank of Canada — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Royal Bank of Canada trades at $215.04 (market cap $294.58B). The key difference: Royal Bank of Canada is far larger — about 7.1× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| BDX | RY | |
|---|---|---|
Market Cap | $41.51B | $294.58B |
Sector | Health | Financials |
52-Week High | $185.39 | $214.04 |
52-Week Low | $135.49 | $128.46 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Royal Bank of Canada (RY) trades at $210.69, down 0.19% on the day, with a bullish technical signal and consistent earnings beats. The stock shows strong fundamentals with a P/E of 19.45, net income margin of 31.85%, and ROE of 17.17%. Recent Q2 2026 earnings of $2.84 per share exceeded expectations, and the company announced a dividend increase to $1.76 per share alongside a share repurchase program.
RY's outlook is supported by robust profitability and shareholder returns, but risks include a high P/B ratio of 3.21 and macroeconomic sensitivity. Analyst sentiment is mixed with a slight hold bias, yet the stock's technical strength and dividend growth present a compelling case for income-focused investors amid cautious market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
